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OBJECTIVES We sought to determine whether the presentation and prognosis of children with complete
atrioventricular block (CAVB) were related to maternal antibody status.
BACKGROUND Comparative studies related to the presence or absence of maternal antibodies anti-SSB/La
and anti-SSA/Ro are lacking in children with isolated complete CAVB.
METHODS From 1980 to 2004, we screened for maternal antibodies in 111 children 15 years old with
CAVB. According to the presence (Ab) or absence (Ab) of antibodies, 2 groups of
patients were retrospectively compared.
RESULTS The study group included 56 Ab and 55 Ab patients with equal gender distribution. A
total of 96% Ab patients were diagnosed in utero or within the first month, compared with
24% Ab patients. Progression from incomplete to complete block was shown in 23 Ab
and 2 Ab patients. Echocardiography showed normal heart structures in Ab patients, but
8 Ab patients had ostium secundum or ductus arteriosus. Pacemaker implantation was
performed in 105 patients, and age at implantation was younger in the Ab group. At
follow-up (age 9.7  6 years), all Ab patients were alive with normal left ventricular
function; dilated cardiomyopathy was diagnosed at diagnosis or during follow-up in 16 Ab
patients, and 6 of 16 have died.
CONCLUSIONS Patients with antibody-mediated CAVB were diagnosed and underwent pacing earlier in life
and had a more severe prognosis than Ab patients because of a high risk of dilated
cardiomyopathy. The absence of antibody suggests a different pathologic mechanism than
autoimmunity, and the term congenital may be not appropriate in these cases. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.07.034Cardiol 2006;48:1682–7) © 2006 by the American College of Cardiology Foundation
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vomplete atrioventricular block (CAVB) is rare in children
ith normal heart structures (i.e., isolated CAVB). Cardi-
logists have long stuck to the idea that isolated CAVB
iagnosed at a “fairly early age” was congenital, even when
iagnosed beyond the neonatal period (1,2). By contrast,
ongenital CAVB is defined by rheumatologists as CAVB
existing at or dating from birth” (3) and more recently as
CAVB diagnosed in utero, at birth, or in the first month of
ife” (4,5). Isolated CAVB diagnosed in utero or at birth is
ften associated with the maternal antibodies anti-SSA
nd/or anti-SSB, and have a more severe prognosis that
hose diagnosed later in life (6–9). However, because many
tudies were retrospective and involved numerous decades,
aternal antibodies status is not always known, especially in
ate onset CAVB (10), and comparative studies related to
aternal antibody status are lacking in children (5). In a
eries of consecutive children with isolated CAVB who had
standard follow-up in our institution since 1980, we
ompared 2 groups of patients to determine whether the
From *Cardiologie Pédiatrique, Université Paris V. René Descartes, Hôpital
ecker-Enfants Malades, Paris, France, and †Service de Médecine Interne, Centre
ospitalier Universitaire Pitié Salpêtrière, Paris, France.t
Manuscript received February 27, 2006; revised manuscript received June 26, 2006,
ccepted July 3, 2006.linical presentation and the prognosis of this condition
ere related to the presence of maternal antibodies.
ETHODS
he study was performed using the diagnostic database of
he Department of Paediatric Cardiology at Necker
nfants-Malades in Paris. All cases of isolated CAVB
iagnosed between 1980 and 2004 in children15 years old
ere included in the study. Patients born before 1980 were
xcluded because of the major progress in prenatal diagnosis
nd neonatal management of CAVB, as well as in pacing
echnology. Patients with traumatic or postoperative block
ere excluded from the study, as well as those with
yocarditis, neuromuscular disorders, metabolic diseases
such as mitochondrial diseases), and significant congenital
eart disease likely to account for CAVB and long QT
yndrome. Patients with minor abnormalities (atrial septal
efects, patent ductus arteriosus, mild pulmonary stenosis)
ere included in the study because these defects have
lready been described in association with maternal anti-
odies (11).
Complete atrioventricular block was defined by atrio-
entricular dissociation with a ventricular rate lower than
he atrial rate. The time of detection of CAVB was taken
a
a
m
d
a
l
H
h
k
e
v
m
g
v
w
i
s
T
fi
p
M
t
a
n
S
p
a
t
r
t
g
a
A
S
s
y
w
f
c
R
O
fi
1683JACC Vol. 48, No. 8, 2006 Villain et al.
October 17, 2006:1682–7 Complete Block in Childrens the earliest documentation of a patient’s conduction
bnormality. Data collected included demographic infor-
ation, patient age at presentation, echocardiographic
ata, pacemaker (PM) intervention procedure, and status
t follow-up.
Our indications for pacing followed the guidelines estab-
ished by the American College of Cardiology/American
eart Association (12). Since 1980, our current approach
as been to implant venous leads in children who are 10
g and to surgically pace children who are 10 kg;
picardial electrodes were initially sutured on the right
entricular apex and on the left ventricular apex in the 5
ost recent patients. Double-chamber PMs were pro-
rammed with a maximum heart rate of 180 beats/min;
entricular rate-responsive PM systems were programmed
ith a maximum ventricular rate of 120 to 150 beats/min.
All children had regular follow-up in our institution,
ncluding at least 2 visits per year with assessment of clinical
tatus, electrocardiogram (ECG), and echocardiography.
Table 1. Characteristics of Patients According
AB
50
Number of patients 5
Gender 30 M
Age at diagnosis
Fetal 5
Neonatal (1 month)
1 yr
1–5 yrs
5 yrs
Diagnosis of AVB
Bradycardia 5
Heart murmur
Syncope
Fatigue, dizziness
Mean heart rate [range] (beats/min) 51  11
Incomplete CAVB
Cardiac malformations 5 ASD, 3
Pacemaker implantation 5
Age at pacing
Neonates 2
1 yr
1 yr 1
Type of pacing 40 epi, 12
Mode of pacing 34 DDD,
Survivors without DCM 4
Age at follow-up (yrs) 4.6  3.
DCM 16 (2
Death 6 (1
ASD  atrial septum defect; CAVB  complete atriovent
Abbreviations and Acronyms
CAVB  complete atrioventricular block
DCM  dilated cardiomyopathy
ECG  electrocardiogram
PM  pacemakerchamber pacemaker; endo  endocardial; epi  epicardial; F  fem
PDA  patent ductus arteriosus; PM  pacemaker; PS  pulmonhe diagnosis of dilated cardiomyopathy (DCM) was de-
ned as left ventricular end diastolic diameter 97th
ercentile associated with a shortening fraction 25%.
aternal antibody determination. The screening for an-
ibodies was performed in mothers of children with CAVB
nd in patients3 months old. Maternal antibodies to soluble
uclear antigens 48-kd SSB/La, 52-kd SSA/Ro, and 60-kd
SA/Ro were detected using quantitative radioligand assays as
reviously described (13). Before the year 2000, anti-SSA and
nti-SSB autoantibodies were detected and quantified using
he classic Ouchterlouny double diffusion technique. For this
eason, mothers of patients with CAVB who had been found
o be negative before 2000 were re-investigated using radioli-
and assays. Patients were assigned to 2 different groups
ccording to the presence (group Ab) or the absence (group
b) of maternal antibodies.
tatistical analysis. Data were expressed as mean value 
tandard deviation and median and range. Statistical anal-
sis comparing 2 groups (Ab) and (Ab) was performed
ith unpaired 2-tailed t testing for the means or chi-square
or categorical variables. All p values of 0.05 or less were
onsidered significant.
ESULTS
ne hundred thirty-six children with isolated CAVB ful-
lled the inclusion criteria. Among them, 25 were excluded
ntibody Status
p AB Group
49.5%
Significant
p value
55 NA
24 M/31 F NS
0.0000001
6
7
8
29
5
0.000186
37
13
2
4
80] 48  11 [30–75] NS
23 0.000001
, 1 PS 0.0059
53 NS
0.000052
9
3
41
20 epi, 33 endo 0.00005
I-R 28 DDD, 25 VVI-R NS
55 0.000018
–23) 11.5  5.6 (2–24) 0.0000001
) 0 (0%) 0.000018
) 0 (0%) 0.037788
block; DCM  dilated cardiomyopathy; DDD  double-to A
Grou
.5%
6
/26 F
0
4
1
1
0
5
1
[35–
2
PDA
2
8
6
8
endo
18 VV
0
8 (0.6
8.5%
0.5%
ricular
ale; M  male; NA  not applicable; NS  not significant;
ary stenosis; VVI  ventricular single-chamber pacemaker.
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Complete Block in Children October 17, 2006:1682–7rom our study because they lived abroad and were lost to
ollow-up or because the information about maternal anti-
odies was not available. Therefore, 111 children were
ncluded in the study; maternal antibodies were present in
6 cases and absent in 55 cases. Table 1 summarizes the data
btained in the 2 groups. No differences were seen between
oth groups for gender distribution.
ge at diagnosis. Fifty-six cases were diagnosed prenatally.
he mean term at diagnosis was 26.2  9 weeks gestation
median 24 weeks, range 18 to 38 weeks). The rate of
remature delivery (37%) and the proportion of low-birth-
eight infants (66% 25th percentile and 18% 10th per-
entile) were high in this subgroup. Fifty children belonged to
he Ab group and 6 to the Ab group (p 0.0001). Among
0 children diagnosed between birth and 1 year of age, 11 were
1 month (4 Ab, 7 Ab) and 9 between 1 and 12 months
1 Ab, 8 Ab) old. In the Ab group, 54 of 56 (96%) of the
AVB were diagnosed in utero or within the first month of
ife versus 13 of 55 (24%) in the Ab group (p  0.0001).
hirty-four of 35 patients diagnosed with CAVB after 1 year
f age belonged to the Ab group.
haracteristics of AVB at the time of diagnosis. The
ean heart rate at diagnosis of CAVB was 51  11
eats/min (range 35 to 80) in the Ab group versus 48 
1 beats/min (range 30 to 75) in the Ab group.
Only 2 patients in the Ab group initially had documented
ncomplete block, both in utero, which progressed to CAVB
fter birth. Conversely, 23 of 56 patients in the Ab group had
proven incomplete block before completion (p 0.0001). In
of 6 fetuses, 4 of 7 neonates, 8 of 8 infants, and 9 of 29
hildren older than 1 year belonging to the Ab group, 24-h
CG monitoring at the time of diagnosis displayed 1:1
able 2. Characteristics of Patients With Dilated Cardiomyopath
Age at Diagnosis
of CAVB
(Weeks)
Echocardiography
at Birth
Age at Diagnosis
of Late DCM
1 F 18 ASD, DCM
2 F 20 PDA, PS, DCM
3 F 20 DCM
4 F 21 DCM
5 F 22 DCM
6 F 24 DCM
7 F 26 DCM
8 F 26 ASD, DCM
9 F 35 DCM
10 NN DCM
11 F 22 Normal 3 months
12 F 27 Normal 3 months
13 F 19 PDA 4 months
14 F 20 PDA 4 yrs
15 F 22 Normal 12 yrs
16 NN ASD 16 yrs fetus; HT  heart transplant; NN  neonate; NYHA  New York H
esynchro  resynchronization; VVI-R  rate-responsive ventricular pacemaker; w  weetrioventricular conduction with a long PR interval and epi-
odes of second-degree AVB.
chocardiographic data at diagnosis. All children in the
b group had normal heart structures. In the Ab group, 5
atients had an ostium secundum, requiring closure in 4 cases
3 surgeries, 1 percutaneous closure) and no intervention in 1
ase; 3 patients had a patent ductus arteriosus that was closed
urgically in 2 and percutaneously in 1. One patient with a
uctus arteriosus also had a mild pulmonary stenosis.
At the time of diagnosis, left ventricular function was
ormal in all Ab patients, whereas 9 Ab patients had
eft ventricular DCM.
M implantation. Pacemaker implantation was performed
n 105 of 111 patients, 52 in the Ab group and 53 in the
b group (p  NS). Prophylactic pacing was decided in
3 asymptomatic patients according to a low heart rate (n
6), prolonged pauses (n  10 patients), and/or frequent
remature ventricular beats (n  7), with no difference in
he indications between the 2 groups. Twelve patients had
ymptoms: cardiac failure in 4 neonates, all with heart rates
45 beats/min, episodes of dizziness and/or asthenia in 6
b children, and syncope in 2 Ab children.
Age at PM implantation was younger in the Ab group:
5% (34 of 52) of the children in the Ab group were paced
efore 1 year of age, versus 23% (12 of 53) in the Ab
roup (p  0.0001). Consequently, the proportion of
picardial system in the Ab group was higher, but there
as no significant difference in the proportion of single and
ouble chambers between both groups (Table 1).
utcome. After a mean follow-up of 9  6 years (median
.7 years; range 6 months to 24 years), all patients in the
at PM
antation
Mode of
Pacing
Age at
Death (yrs)
Age at
Follow-Up (yrs) Status
N DDD 14 NYHA II
DCM
onths VVI-R 3
N DDD 1
N VVI 2
N DDD 2 HT list
N DDD 1 Normal
onths DDD 1 DCM
N VVI-R 4
N VVI NN
N VVI-R 10 Normal
N DDD 3 DCM
N DDD 2 Normal
onths DDD 5 DCM
Resynchro
rs DDD 7 DCM
NYHA II
rs DDD 12 Resynchro
N VVI-R 24 DCM
NYHA IIy
Age
Impl
N
3 m
N
N
N
N
6 m
N
N
N
N
N
4 m
5 y
1 y
Neart Association classification for heart failure; PS  pulmonary stenosis;
ks gestation. Other abbreviations as in Table 1.
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October 17, 2006:1682–7 Complete Block in Childrenb group (mean age 11.5  5.6 years) were alive, and all
ad normal left ventricular function on echocardiography.
Conversely, 6 patients died in the Ab group. Of note,
CM was observed only in this subgroup of patients, as 16
f 56 had a DCM during follow-up (Table 2). In these 16
atients, the AV block was diagnosed in utero in 14 or at
irth in 2. The diagnosis of DCM was done in fetal life or
t birth in 10 patients (patients 1 to 10) and DCM
eveloped during follow-up in the remaining 6 (patients 11
o 16), in whom it was diagnosed by systematic echocardi-
graphy (4 cases) or according to heart failure (2 cases). In
2 patients, DCM was present before PM implantation and
id not worsen after pacing. In the other 4 patients, DCM
eveloped after PM implantation; duration of pacing before
iagnosis of DCM was 4 months in 2 cases (patients 11 and
2), 12 years in patient 15, and 16 years in patient 16. We
id not find any difference in the PM programming between
atients with DCM and patients with normal left ventric-
lar function.
All deaths were related to DCM. One neonate with
CM from fetal life died of low cardiac output shortly after
M implantation (patient 9), and the 5 other patients died
f cardiac failure, between 6 months and 12 years of age.
mong the 10 survivors with DCM, 2 underwent successful
ardiac resynchronization, 1 is awaiting heart transplanta-
ion, and 7 received chronic medication including beta-
lockers and/or angiotensin-converting enzyme inhibitors.
ISCUSSION
he term congenital CAVB has been coined by pediatric
ardiologists to define atrioventricular block in children with
ormal heart structures. It has long been supposed that all
AVB diagnosed in childhood were congenital and that the
iagnosis had been delayed because of a high ventricular rate
r absence of symptoms. However, our study confirms that
here are indeed 2 different diseases with regard to the
resence of maternal antibodies status. Furthermore, we
how here that the outcome of CAVB is closely related to its
mmune origin.
ge at diagnosis and mechanism of block. When the
lock is diagnosed in the fetus or in the neonate, it is
redominantly associated with maternal anti-Ro/SSA
nd/or anti-La/SSB antibodies, which enter the fetal circu-
ation and trigger an inflammatory response, leading to
brosis of the conduction system (14–16). In our series, 54
f 56 AVBs diagnosed in utero, 4 of 11 AVBs diagnosed in
eonates, and only 2 of 44 AVBs diagnosed after 1 month
f age were associated with maternal antibodies; when
AVB was diagnosed after 5 years of age, no maternal
ntibodies were found. In recent series and with the most
ensitive and advanced methods, maternal autoantibodies
ere found in nearly 100% of patients diagnosed in utero
ut only in a minority of children diagnosed after the
eonatal period (2,6,7,10,17–21). Because it has been
hown that once maternal antibodies have been detected, they remain lifelong in mothers’ sera (21,22), their absence
uggests that other mechanisms must be involved in the
athogenesis of the AVB. Thus, the denomination
ntibody-associated CAVB would be more appropriate than
olely congenital CAVB when referring to the subgroup of
atients with autoantibody-associated CAVB.
We found that 3 of 56 children in the Ab group versus
3 of 55 in the Ab group had progression from incom-
lete to complete AVB, mostly after birth. Although there
s clear documentation that incomplete block can progress
fter birth in children with antibody-associated CAVB,
espite the clearance of maternal antibodies from the
eonatal circulation (18,23), others have found that this
rogression occurs more frequently in the absence of ma-
ernal antibodies (6). These data add further evidence
howing that isolated CAVB may be related to a degener-
tive process involving the conduction tissue and occurring
ften after birth, making the denomination congenital
nappropriate.
ssociated structural anomalies. By definition, autoantibody-
ediated CAVB occurs in children without cardiac abnor-
alities that would be causal for the development of the
lock. However, miscellaneous cardiac lesions, mainly os-
ium secundum and ductus arteriosus, were found frequently
n the Ab group (8 cases), whereas none were noticed in
he Ab group. Accordingly, cardiac structural lesions have
een reported in 16% to 42% of children with antibody-
ssociated CAVB (10,18), and such lesions have also been
oticed in infants without CAVB born to anti-SSA/Ro-
ositive mothers (24).
anagement of children with CAVB. The prognosis of
AVB in children is influenced by age, and numerous series
ave reported that patients detected in utero or at birth have
poorer outcome than those diagnosed later in life
8,9,18,25–27). In retrospective series covering multiple
ecades, the high mortality and morbidity of neonates with
AVB were mainly related to prematurity, delayed initia-
ion of pacing therapy, and difficulties in pacing very young
hildren. Improvement in management of these high-risk
regnancies (i.e., development of fetal echocardiography
nd transfer of pregnant patients with affected fetuses to
ighly specialized centers) and in the initial management of
eonates has changed the prognosis of CABV (8). Accord-
ngly, in our series, the only neonatal death occurred in a
remature baby who had been delivered by cesarean section
ecause of a very severe DCM.
In neonates, the mechanism of CAVB did not influence
he timing of PM implantation because 9 of 13 Ab and 28
f 54 Ab infants were paced before 1 month of age. There
as no death related to PM implantation in neonates (28).
All together, 94.5% of our patients were paced before
hey reached 15 years of age, and with the development of
rophylactic pacing, the majority of patients with CAVB
ow undergo PM implantation in childhood. There was no
udden death, and 2 patients had syncope; in 1 case it was
he first symptom of CAVB in a previously healthy child,
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Complete Block in Children October 17, 2006:1682–7nd the other child was followed up in another department,
here prophylactic pacing had not been proposed despite a
eart rate of 45 beats/min. These results confirms that
rophylactic pacing has considerably decreased the inci-
ence of previously reported severe complications such as
yncope or sudden death in children with isolated CAVB
9,26,27,29,30).
ongenital CAVB and DCM. In the whole group of
hildren, 16 of 111 (14.4%) have developed DCM. This
igh incidence is probably the consequence of the high
umber of patients who had an early diagnosis in our
opulation. All 16 patients had been diagnosed with CAVB
n utero or at birth, so that the incidence of DCM in this
ubgroup is 29.5% (16 of 54). In 10 cases, the diagnosis of
CM was made during fetal life or during the neonatal
eriod. In the 6 remaining patients, DCM was diagnosed
uring follow-up. DCM has already been described with a
igh incidence in children with early diagnosed CAVB
10,31–33). Among 149 children with CAVB, Udink ten
ate et al. (32) identified 9 patients (6%) who developed
CM at a mean age of 6.5  5 years; however, when
onsidering the group of 34 patients diagnosed in utero, 8 of
hem developed DCM (23%). In a retrospective series of 91
hildren with CAVB diagnosed in utero or at birth, Eronen
t al. (10) have reported an incidence of 23% of DCM that
as diagnosed before 3 years of age in all cases. Moak et al.
31) have reported 16 infants who had normal left ventric-
lar function at the time of diagnosis of congenital CAVB
nd who developed a DCM between 2 weeks and 30
onths of age in 13 cases and later in life (5.8  3 years) in
cases. Thus, close echocardiographic follow-up is war-
anted in children with CAVB, even when left ventricular
arameters are initially considered normal.
In our series, none of the Ab patients and 16 Ab
atients (28.5%) had DCM. In others series, although
CM was mainly described in children with CAVB diag-
osed in utero or at birth, no correlation was established
etween maternal autoimmunity and DCM because sero-
ogic findings were often lacking, especially in mothers of
hildren with late-onset heart block. To our knowledge, our
tudy is the first to compare 2 groups of children with
solated CAVB, according to maternal antibody status, and
o show the association between antibody-mediated CAVB
nd a high risk of DCM. It adds further evidence to suggest
hat children with antibody-associated CAVB have myocar-
ial damage caused by the inflammatory process, which may
rogress or be reactivated during follow-up (11,16,31,34–36).
Pacemaker-induced DCM has been offered as a possible
tiologic factor because right ventricular pacing induces
yocardial dystrophic changes and adverse remodeling
aused by ventricular desynchronization. This seems un-
ikely in our series because the majority of paced children
id not develop DCM and the majority of patients with
CM developed it before being paced. Cruz et al. (37) have
eported in an adult series that cardiac failure after PM
mplantation was observed only in patients with heart blockssociated with maternal antibodies. Moreover, DCM has
een reported in unpaced patients with CAVB, which was
he case in 12 of our patients, and more recently in fetuses
nd infants with maternal antibodies, in the absence of any
onduction anomaly (11). However, this subgroup of chil-
ren with maternal antibodies and preexisting myocardial
amage may be particularly at risk for pacing-induced
ardiomyopathy.
The prognosis of patients in whom DCM developed was
ery poor; 6 of them died and 1 is awaiting transplantation.
his severe prognosis of DCM is reported in all series,
espite early diagnosis of DCM and medical treatment.
ardiac resynchronization was performed in 2 patients,
ith good clinical result, and others have been stabilized
ith medical therapy.
In conclusion, our study suggests that 2 different forms of
solated CAVB should be differentiated in children. Con-
enital CAVB is usually associated with maternal antibod-
es, is increasingly diagnosed in utero, and despite early
acing, still carries significant morbidity and mortality
ecause of a high incidence of DCM. Long-term prognosis
s difficult to predict because DCM is not always obvious at
iagnosis, and prolonged echocardiographic monitoring of
hese patients is mandatory. In children whose mothers have
o antibodies, the block is often progressive and diagnosed
ater in life, its etiology remains unknown, and these
hildren have a good prognosis when usual prophylactic
ecommendations for PM implantation are applied.
tudy limitations. Twenty-five patients, representing 20%
f potential enrollees, were excluded from the study because
f lack of antibody status. Fifteen of these patients did not
ave the same clinical profile as those included in the study:
hey lived abroad, were diagnosed later than the patients in
ur series (neither neonate nor infant), and were sent to
aris only for PM implantation. Twenty other patients,
iagnosed before 1988, are now followed up by adult
ardiologists or are lost to follow-up; in addition to antibody
tatus, initial echocardiography was often lacking or impre-
ise in these patients.
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